Working… Menu
Trial record 1 of 1 for:    DONIMI
Previous Study | Return to List | Next Study

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04133948
Recruitment Status : Recruiting
First Posted : October 21, 2019
Last Update Posted : June 1, 2020
Information provided by (Responsible Party):
The Netherlands Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : March 2024